Bortezomib

Drug Profile

Bortezomib

Alternative Names: LDP-341; MG-341; MLN-341; NSC-681239; PS 0341; PS-341; Velcade

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Duke University; Erasmus MC; Genentech; Hoosier Cancer Research Network; HOVON Foundation; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson; Millennium; Millennium Pharmaceuticals; Takeda Oncology
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma
  • Registered B cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Acute lymphoblastic leukaemia; Glioma; Graft-versus-host disease; Non-Hodgkin's lymphoma
  • Phase I/II Waldenstrom's macroglobulinaemia
  • Phase I Hodgkin's disease; Malignant melanoma
  • Preregistration Submission Withdrawal Follicular lymphoma
  • No development reported Pancreatic cancer
  • Discontinued Adenocarcinoma; Amyloid light-chain amyloidosis; Cerebral ischaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Non-small cell lung cancer; Prostate cancer; Rheumatoid arthritis; T cell prolymphocytic leukaemia

Most Recent Events

  • 21 Sep 2016 Phase-II clinical trials in Acute lymphoblastic leukaemia (Combination therapy, In children, In infants, In adolescents, Second-line therapy or greater) in Japan (IV) (UMIN000023815)
  • 16 Sep 2016 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 01 Sep 2016 University Health Network completes enrolment in its phase II trial for Multiple myeloma (Newly diagnosed, Second-line therapy or greater) in Canada (NCT00570180)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top